A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease
Joanne Kurtzberg(Duke University), Donna Skerrett(Mesoblast (United States)), Vinod K. Prasad(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Annie Cheng(University of Glasgow), Paul A. Carpenter(Fred Hutch Cancer Center), Eneida R. Nemecek(Oregon Health & Science University), Kris M. Mahadeo(Duke University), Prakash Satwani(Pediatrics and Genetics), Susan E. Prockop(Memorial Sloan Kettering Cancer Center), Jack Hayes(Mesoblast (United States)), Hisham Abdel‐Azim(University of Southern California), Sonali Chaudhury(Northwestern University), Biljana Horn(UF Health Shands Hospital), Steven Neudorf(Children's Hospital of Orange County), Elizabeth Burke(Mesoblast (United States)), Troy C. Quigg(CHRISTUS Transplant Institute)
Cited by 201
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
|Biology of Blood and Marrow Transplantation|2015|409
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369